These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38265606)

  • 1. Relationship between patent foramen ovale anatomical features and residual shunt after patent foramen ovale closure.
    Nakayama R; Takaya Y; Akagi T; Takemoto R; Haruna M; Nakashima M; Miki T; Nakagawa K; Toh N; Nakamura K
    Cardiovasc Interv Ther; 2024 Apr; 39(2):200-206. PubMed ID: 38265606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale.
    Susuri N; Obeid S; Ulmi M; Siontis GCM; Wahl A; Windecker S; Nietlispach F; Meier B; Praz F
    EuroIntervention; 2017 Sep; 13(7):858-866. PubMed ID: 28437244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices.
    Sorensen SG; Aguilar H; McKnight WK; Thomas H; Muhlestein JB
    J Interv Cardiol; 2010 Dec; 23(6):575-80. PubMed ID: 20796165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial Septal Aneurysm, Shunt Size, and Recurrent Stroke Risk in Patients With Patent Foramen Ovale.
    Turc G; Lee JY; Brochet E; Kim JS; Song JK; Mas JL;
    J Am Coll Cardiol; 2020 May; 75(18):2312-2320. PubMed ID: 32381162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla
    Neuser J; Akin M; Bavendiek U; Kempf T; Bauersachs J; Widder JD
    BMC Cardiovasc Disord; 2016 Nov; 16(1):217. PubMed ID: 27832757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of residual shunt rates in five devices used to treat patent foramen ovale.
    Matsumura K; Gevorgyan R; Mangels D; Masoomi R; Mojadidi MK; Tobis J
    Catheter Cardiovasc Interv; 2014 Sep; 84(3):455-63. PubMed ID: 24550064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual Shunt after Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data.
    Moon J; Kim M; Oh PC; Shin DH; Park HM; Jo YY; Lee JS; Kang WC
    J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):347-353. PubMed ID: 30396838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual Shunt After Patent Foramen Ovale Closure and Long-Term Stroke Recurrence: A Prospective Cohort Study.
    Deng W; Yin S; McMullin D; Inglessis-Azuaje I; Elmariah S; Hung J; Lo EH; Palacios IF; Buonanno FS; Ning M
    Ann Intern Med; 2020 Jun; 172(11):717-725. PubMed ID: 32422058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplatzer or Figulla Flex II Occluder: a comparative study of outcomes after transcatheter patent foramen ovale closure.
    Toggweiler S; Moccetti F; Conrad N; Loretz L; Madanchi M; Bossard M; Attiger-Toller A; Cuculi F; Wolfrum M
    J Invasive Cardiol; 2024 Apr; 36(4):. PubMed ID: 38412438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
    Aral M; Mullen M
    Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale.
    Gevorgyan Fleming R; Kumar P; West B; Noureddin N; Rusheen J; Aboulhosn J; Tobis JM
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):365-372. PubMed ID: 31654558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study.
    Marchese N; Pacilli MA; Inchingolo V; Fanelli R; Loperfido F; Vigna C
    EuroIntervention; 2013 Jul; 9(3):382-8. PubMed ID: 23872652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter closure of patent foramen ovale associated with atrial septal aneurysm with Amplatzer Cribriform septal occluder.
    Musto C; Cifarelli A; Pandolfi C; De Felice F; Fiorilli R; Caferri G; Violini R
    J Invasive Cardiol; 2009 Jun; 21(6):290-3. PubMed ID: 19494408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-Market Clinical Follow-Up With the Patent Foramen Ovale Closure Device IrisFIT (Lifetech) in Patients With Stroke, Transient Ischemic Attack, or Other Thromboembolic Events.
    Sievert K; Yu J; Bertog S; Hornung M; von Bardeleben RS; Gafoor S; Reinartz M; Matic P; Hofmann I; Grunwald I; Schnelle N; Sievert H
    Cardiovasc Revasc Med; 2021 Sep; 30():72-75. PubMed ID: 33097460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Atrial Septal Aneurysm and Shunt Size With Stroke Recurrence and Benefit From Patent Foramen Ovale Closure.
    Mas JL; Saver JL; Kasner SE; Nelson J; Carroll JD; Chatellier G; Derumeaux G; Furlan AJ; Herrmann HC; Jüni P; Kim JS; Koethe B; Lee PH; Lefebvre B; Mattle HP; Meier B; Reisman M; Smalling RW; Sondergaard L; Song JK; Thaler DE; Kent DM
    JAMA Neurol; 2022 Nov; 79(11):1175-1179. PubMed ID: 36215079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Transesophageal Echocardiography in Amplatzer Atrial Septal Defect Occluder for Percutaneous Closure of Large Patent Foramen Ovale.
    Du Y; Xie H; Shao H; Cheng G; He L; Wang X; He X; Lan B; Zhang Y; Tian G
    Cardiovasc Ther; 2022; 2022():3226080. PubMed ID: 35936794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transseptal puncture to facilitate device closure of "long-tunnel" patent foramen ovale.
    Thompson AJ; Hagler DJ; Taggart NW
    Catheter Cardiovasc Interv; 2015 May; 85(6):1053-7. PubMed ID: 25380406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent foramen ovale closure devices.
    Shafi NA; McKay RG; Kiernan FJ; Silverman IE; Ahlquist M; Silverman DI
    Int J Cardiol; 2009 Nov; 137(3):314-6. PubMed ID: 19616327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Experience of Percutaneous Patent Foramen Ovale Closure Using the Amplatzer PFO Occluder in Japanese Patients to Prevent the Recurrence of Cryptogenic Stroke.
    Takafuji H; Obunai K; Makihara Y; Kato N; Watanabe H
    Intern Med; 2021 Nov; 60(21):3385-3390. PubMed ID: 34024855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.